GE HealthCare Showcases Over 40 AI-Integrated Innovations at RSNA 2024 to Advance Precision Medicine

● GE Healthcare (Booth #7330) showcased multiple innovative achievements addressing challenges in the healthcare service field, covering the entire process from medical equipment to disease solutions and digital tools.

● Many innovations are the result of GE Healthcare's continued increased investment in R&D since 2022.

December 1, 2024, Chicago – At the 2024 Radiological Society of North America (RSNA) annual meeting, GE Healthcare showcased more than 40 innovative technologies and solutions, including multiple artificial intelligence (AI) innovations and solutions, committed to enhancing patient care, improving diagnostic efficiency, and advancing precision medicine.

GE Healthcare's innovative achievements displayed at RSNA aim to further enhance diagnostic and treatment efficiency by seamlessly integrating data to promote precision medicine across various clinical pathways. These innovations represent the results of GE Healthcare’s relentless efforts in recent years to deeply integrate AI with medical services as part of its digital strategy, which focuses on continuously driving the fusion of AI with equipment, and developing more AI and digital tools to empower clinical decision-making and improve disease diagnosis and treatment outcomes.

The American Society of Radiologic Technologists (ASRT) surveyed more than 8,000 radiology professionals and released a report in 2024. The results showed that over half of the respondents reported feeling extremely emotionally exhausted, and 57% felt they were not valued or recognized at work.

GE Healthcare Global President and CEO Peter Arduini stated, "The challenges faced by radiologists are increasingly intensifying, placing immense pressure on medical imaging and disease diagnosis. Addressing the most pressing concerns of imaging professionals through technological innovation is at the core of GE Healthcare's mission. We are leveraging the latest AI and digital technologies to develop innovative solutions at the equipment level, across clinical pathways, and in enterprise collaborations, covering the entire process from diagnosis to treatment to recovery. These efforts aim to empower healthcare workers to deliver more personalized, precise, and compassionate medical care."

GE Healthcare is bringing more simplified and efficient workflows through next-generation solutions and AI-driven products, helping clinicians improve diagnostic efficiency, better serve patients, and enhance patient outcomes. At this exhibition, GE Healthcare showcased the following efficient workflow tools and products:

· Clarify DL，An AI technology-driven bone image reconstruction algorithm can help improve SPECT image quality and enhance diagnostic confidence (currently under U.S. 510(k) review.)

· nCommand Lite by IONIC HealthSupports remote imaging scans, including remote scanning assistance for MRI, CT, and PET/CT, enabling radiologists to focus more on patient care.

· True PACS and v7 PACS Solution, Now SupportedBlackford’s AI collaboration platform and third-party AI imaging application tools can be seamlessly integrated into the film-reading workflow, assisting radiology and clinical teams in achieving rapid and precise diagnoses. This collaboration allows customers of True PACS and v7 PACS solutions to directly access Blackford Analysis' AI platform as well as a range of third-party AI applications, covering multiple clinical fields from breast imaging to lung scans. (This application is not available in all countries and markets.)

· MR Max 3™, Adopting a wireless and needle-free design for gadolinium-based contrast agents, it is compatible with various sizes of contrast agent bottles, including 24-hour multi-purpose containers, greatly enhancing usage flexibility, improving work efficiency, reducing plastic waste consumption, minimizing contrast agent waste, and thereby significantly lowering overall operational costs.

· Caption Guidance™，Driven by a deep learning image analysis algorithm, it can provide real-time guidance to doctors for adjusting the ultrasound probe, ensuring that the acquired cardiac ultrasound images meet diagnostic standards.

· Venue Sprint™, the latest product in the Venue series, provides high-quality scanning and support for clinical ultrasound scenarios with its excellent portability and advanced features. The Venue ultrasound family will also integrate the wireless handheld ultrasound Vscan Air with a dual-sided probe and incorporate the Caption Guidance application.

· Vscan Air SL, the latest Applause ultrasound equipped with Caption AI, including Caption Interpretation AutoEF software, can automatically calculate left ventricular ejection fraction (LVEF), quickly assess the heart and blood vessels, and help clinicians rapidly diagnose and make treatment decisions for cardiovascular diseases. Additionally, digital tools enable Vscan Air to securely store and share images in the cloud.

GE Healthcare is committed to providing personalized treatment solutions for patients and strong support for healthcare systems. GE Healthcare’s comprehensive oncology portfolio combines AI, digital technologies, imaging, and diagnostic pharmaceuticals to help physicians enhance diagnostic confidence, improve diagnostic efficiency, and optimize patient services and treatment outcomes.

· AuroraIt is a new type of dual-head SPECT/CT that integrates deep learning image reconstruction technology (Clarify DL) and a series of advanced CT clinical and workflow solutions, dedicated to solving operational and diagnostic challenges for clinicians while providing patients with personalized and precise diagnosis and treatment. (Under U.S. 510(k) review)

· GE Healthcare and RadNet recently announced a strategic partnership aimed at leveraging GE Healthcare's expertise and innovations in medical imaging, along with RadNet’s DeepHealth AI technology solutions, to further advance AI innovation and commercial implementation in the imaging field. Through this collaboration, GE Healthcare and DeepHealth will jointly develop SmartTechnology™ solutions, utilizing AI to enhance radiology workflows and address key challenges in the imaging value chain. This effort aims to improve clinical efficiency, increase diagnostic accuracy, and ultimately elevate patient care.

· Senographe Pristina Via It is a leading mammography system that brings a smoother workflow and simplifies the image acquisition process through a series of innovative features.

· CareIntellect for OncologyIt is a brand-new cloud-based application that can aggregate multimodal patient data from different systems into a unified view, and use generative artificial intelligence to summarize clinical data and reports. This helps doctors quickly grasp disease progression and assist in decision-making and planning for the next steps in treatment. The application is planned to launch in the United States in 2025, initially targeting the treatment of prostate cancer and breast cancer. Tampa General Hospital and UT Southwestern Medical Center will be the first evaluators of CareIntellect for Oncology.

Theranostics is a rapidly evolving field of molecular imaging that utilizes tracers and diagnostic imaging equipment, including PET and SPECT systems, for accurate diagnosis and disease monitoring, while providing precise targeted treatments for patients. These therapeutic and diagnostic technologies work together to offer highly personalized, accurate, and patient-centered solutions for medical diagnosis and treatment. GE Healthcare also showcased innovative technologies related to theranostics at this event.

Roland Rott, President and CEO of GE Healthcare's Global Medical Imaging Business, stated: "Personalized treatment plans are essential in the continuum of cancer care, covering the entire process from early screening and diagnosis to treatment planning and efficacy evaluation, with the goal of improving treatment outcomes. With comprehensive solutions and extensive expertise in the healthcare industry, GE Healthcare is able to integrate diagnostic information with treatment decisions, supporting every step of the care pathway to achieve more effective treatments."

GE Healthcare recently announced a series of innovative achievements related to diagnosis and treatment, including:

• MINItrace Magni（MI）The cyclotron adopts a more compact and cost-effective design, utilizing solid target technology to achieveThe in-hospital production of PET tracers and radiopharmaceuticals has now improved the accessibility of theranostics.

• Omni Legend (21 cm configuration),It is a device evolved based on the needs of the medical system, capable of shortening scan time and maintaining image quality without sacrificing dose reduction for tumor imaging; supporting PET amyloid imaging in neuroimaging to aid in the diagnosis and treatment of Alzheimer's disease; and supporting multiple tracers in cardiology, providing excellent cardiac diagnostics to help doctors enhance their capabilities.Diagnostic Confidence. Precision Based on Deep Learning Image Processing TechnologyDL is the unsung hero behind these remarkable capabilities. Compared to traditional Time-of-Flight (ToF) PET/CT devices, this technology enhances the ability of PET/CT to detect small and low-contrast lesions.

• Flyrcado（F18 Flurpiridaz）The tracer is the first PET MPI (Positron Emission Tomography Myocardial Perfusion Imaging) drug approved by the U.S. FDA, used to enhance the detection of coronary artery disease.Disease (Diagnostic Effect of CAD).

• GE HealthcareMIM SoftwareHas obtained U.S. FDA Monte Carlo dose measurement approval, which is the use of the Monte Carlo method for radionuclide absorbed dose calculation.After obtaining permission, you can useMIM SurePlan MRTSoftware for Monte Carlo dose measurement,SurePlan MRT adopts the Dose Planning Method (DPM) to achieve theranostics.Automation and standardization of measurements. (This technology is not applicable in all countries/markets.)

In addition, the following innovative devices and digital technologies were also highlighted:

· Versana PremierUltrasound EquipmentEquipped with multiple automation and artificial intelligence productivity tools, it can help doctors streamline workflows, improve work efficiency, and bring faster imaging speed and clearer image quality to clinical diagnosis and treatment. The exhibited equipment includes the Digital Expert Connect tool, which allows users to easily collaborate and interact virtually with colleagues and peers in different locations, providing real-time training and support before, during, and after examinations.

· FDA ApprovedSIGNA MAGNUSIt is a "micro-brain imaging" MRI specifically applied to brain and nervous system examinations, offering better detection capabilities for fine microstructures and lesions in the brain, promoting precision and specialization in the field of neuroscience.

· True Enhance DL on Revolution Ascend platform It is a dedicated deep neural network (DNN) applied on the Revolution Ascend platform, which enhances image contrast, streamlines workflow, and assists clinicians in improving diagnostic accuracy.

· TrueFidelity DL on Revolution Apex and Revolution Ascend platforms. As a deep learning-based image reconstruction technology, it can generate high-definition, low-noise CT images through deep neural networks. For cardiac imaging scenarios, this technology is particularly helpful in reducing noise and enhancing image sharpness, boosting doctors' diagnostic confidence.

For more information about GE Healthcare's showcase and related activities at RSNA 2024, please visit the GE Healthcare official website: our press kit, RSNA 2024 events page.

GE Healthcare is committed to becoming a global leader in innovative medical technology, diagnostic pharmaceuticals, and digital solutions. By providing integrated solutions, services, and data analysis, it enables hospitals to operate more efficiently, clinical diagnoses to be more effective, treatment methods to be more precise, and patients to be healthier and happier. Over its more than 125 years of serving patients and healthcare institutions, GE Healthcare has continuously promoted personalized, interconnected, and more empathetic healthcare while simplifying the patient care process. GE Healthcare's businesses in medical imaging, ultrasound, life care, and diagnostic pharmaceuticals cover every aspect of healthcare from diagnosis, treatment, to monitoring. GE Healthcare was listed on the NASDAQ Stock Exchange in January 2023. The company operates in over 160 countries and regions, with annual revenue exceeding $19.6 billion and a global workforce of 51,000 employees dedicated to creating seamless healthcare.